Yixintang Pharmaceutical Group Co., Ltd.
Simbols: 002727.SZ
SHZ
18.75
CNYTirgus cena šodien
23.9311
P/E koeficients
0.6980
PEG koeficients
11.17B
MRK Cap
- 0.02%
DIV ienesīgums
Yixintang Pharmaceutical Group Co., Ltd. (002727-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3895.3 | 3520 | 2532.4 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 219.7 | 8.4 | 297.3 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 1991.7 | 2411 | 1777.5 | |||||||||||||||
balance-sheet.row.inventory | 0 | 3852.6 | 3387.4 | 3317 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 153.3 | 139.2 | 65.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 9892.9 | 9457.6 | 7692.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 3995.6 | 3993.5 | 4080 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 1649.6 | 1397.2 | 1380 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 184.1 | 165.7 | 122.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 1833.7 | 1562.9 | 1502.8 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 165.3 | 131.4 | -190.1 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 88.9 | 94.1 | 58.5 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 670.8 | 939.5 | 1193.8 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 6754.5 | 6721.5 | 6645 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 2560.2 | 4328.8 | 3805.9 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 3333.9 | 1335.5 | 1143.9 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 81.4 | 250.4 | 164.1 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 1552.2 | 1758.5 | 1764.1 | |||||||||||||||
Deferred Revenue Non Current | 0 | 1.2 | 12.2 | 13.3 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 1191.9 | 1055.8 | 12.7 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1557.3 | 1774.7 | 1781 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1552.2 | 1756.7 | 1729 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 8757.1 | 8651.5 | 7664.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 596 | 596 | 596.2 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 4646.4 | 4335.4 | 3504.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 377.8 | 424.9 | 405.6 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2125.8 | 2069.8 | 2071.7 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7746 | 7426.1 | 6577.7 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 131 | 101.4 | 94.8 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 7877 | 7527.6 | 6672.5 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 385 | 139.8 | 107.2 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 4886.1 | 3094 | 2908 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 1210.5 | -417.6 | 672.9 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 549.4 | 1013 | 917.2 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 1000.6 | 1087.8 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 14.2 | 40.4 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | -9.7 | -603.9 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -765.8 | -739.7 | |||||||||||||||
cash-flows.row.inventory | 0 | 0 | -234.9 | -1236.8 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | 1026.1 | 1399.9 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -549.4 | 514.1 | 377.5 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -4.7 | -65.1 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -980.5 | -1976.5 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 1207.2 | 2901.8 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -94.7 | -336.9 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -221.7 | 131.7 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -207.9 | -137.1 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 2 | 0.1 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -0.1 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -191.6 | -180.9 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | -678.6 | -986.8 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | -1078.2 | -1304.8 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0.3 | -0.1 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | 1197.5 | 618.5 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 2859.5 | 2859.5 | 1661.9 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2859.5 | 1661.9 | 1043.5 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | 2497.1 | 1791.7 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | 2148.1 | 1400 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 17301.4 | 17431.6 | 14587.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 11750.3 | 11322.3 | 9196.5 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 5551 | 6109.3 | 5390.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 4717.5 | 4496.8 | 4091.3 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 16467.8 | 15819.1 | 13287.8 | |||||||||||||||
income-statement-row.row.interest-income | 0 | -77.6 | 53.4 | 39.2 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1332.4 | 1000.6 | 1397.7 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 833.5 | 1661.9 | 1067.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 709.9 | 1235 | 1096.5 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 142.2 | 222 | 179.3 | |||||||||||||||
income-statement-row.row.net-income | 0 | 549.4 | 1010 | 921.6 |
Biežāk uzdotie jautājumi
Kas ir Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) kopējie aktīvi?
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) kopējie aktīvi ir 16647375283.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.318.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 3.367.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.031.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.045.
Kāda ir Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 549441525.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 4886107552.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 4717493463.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.